CLEAN – PROTECT – TEST
Q Biotechnologies Ltd is a progressive organisation that develops, manufactures and distributes under exclusive license, products for disease prevention.
Our portfolio includes rapid and accurate testing, persistent surface and skin disinfectants and capital equipment.
Q Biotechnologies joins Q Medical at Manchester Central for Infection Prevention 2017, 18-20th September. Q Medical Technologies can be found on stand 72. During your visit why not try Q Shield for all day protection against harmful bacteria, viruses and fungi. For full information of the event visit IP2017
Pupils at Coleby Church of England Primary School in Lincolnshire took part in an assembly, followed by a workshop on hand hygiene and the immune system for years 5 and 6. The National Institute for Health Care and Excellence (NICE) recently published new guidelines recommending all children and young people should be taught the importance of hand washing to prevent and manage infection. It is hoped that this will have
We are pleased to be chosen as a finalist for the Medilink East Midlands Business Awards 2017 in the category of Collaboration with the NHS for our work adapting our surface sampling technologies to be able to undertake fluidic sample testing of both urine and cerebral spinal fluid samples. Using our Profile 1 rapid bacteria test we are able to diagnose either bacterial or viral cause within 5 mins.
Two-thirds of tested samples of alcohol prep pads tied to a massive recall, serious infections and death were contaminated with dangerous bacteria, including tainted products from eight of 10 separate lots, according to a new government report. Read full article on NBC News
Healthcare antiseptic products used up to 100 times a day by clinicians must prove themselves to be safe and effective, especially over the long haul, to remain on the market under proposed regulations announced today by the US Food and Drug Administration (FDA). The antiseptic products in question are found in hospitals, nursing homes, physician offices, clinics, and other outpatient settings. Their manufacturers would have to submit safety and efficacy